US20070202166A1 - Method for increasing the rate and consistency of bioavailability of supplemental dietary ingredients - Google Patents
Method for increasing the rate and consistency of bioavailability of supplemental dietary ingredients Download PDFInfo
- Publication number
- US20070202166A1 US20070202166A1 US11/709,526 US70952607A US2007202166A1 US 20070202166 A1 US20070202166 A1 US 20070202166A1 US 70952607 A US70952607 A US 70952607A US 2007202166 A1 US2007202166 A1 US 2007202166A1
- Authority
- US
- United States
- Prior art keywords
- ingredient
- fine
- milled
- supplemental dietary
- rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 87
- 230000000153 supplemental effect Effects 0.000 title claims abstract description 51
- 235000012041 food component Nutrition 0.000 title claims abstract description 22
- 239000004615 ingredient Substances 0.000 claims abstract description 87
- 238000003801 milling Methods 0.000 claims abstract description 38
- 235000007882 dietary composition Nutrition 0.000 claims abstract description 29
- 238000004090 dissolution Methods 0.000 claims abstract description 28
- 239000002245 particle Substances 0.000 claims description 78
- 239000000203 mixture Substances 0.000 claims description 22
- 238000010521 absorption reaction Methods 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 18
- 230000037406 food intake Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000001079 digestive effect Effects 0.000 claims 5
- 230000008569 process Effects 0.000 abstract description 19
- 239000000126 substance Substances 0.000 description 47
- CVSVTCORWBXHQV-UHFFFAOYSA-N anhydrous creatine Natural products NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 235000015872 dietary supplement Nutrition 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 11
- 229960003624 creatine Drugs 0.000 description 11
- 239000006046 creatine Substances 0.000 description 11
- 229960004826 creatine monohydrate Drugs 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 7
- 229930064664 L-arginine Natural products 0.000 description 7
- 235000014852 L-arginine Nutrition 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000007894 caplet Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 238000010902 jet-milling Methods 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 150000004715 keto acids Chemical class 0.000 description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000011179 visual inspection Methods 0.000 description 4
- 235000021119 whey protein Nutrition 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- UFUWQSYRGLMLKP-UHFFFAOYSA-N creatine ethyl ester Chemical compound CCOC(=O)CN(C)C(N)=N UFUWQSYRGLMLKP-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036449 good health Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000004246 zinc acetate Substances 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229960004998 acesulfame potassium Drugs 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- SZZVKHCNEZPXOL-UHFFFAOYSA-N ethyl 2-[carbamimidoyl(methyl)amino]acetate;hydrochloride Chemical compound Cl.CCOC(=O)CN(C)C(N)=N SZZVKHCNEZPXOL-UHFFFAOYSA-N 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000006070 nanosuspension Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- -1 L-arginine Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- YJAKVPKJJMFDNW-UHFFFAOYSA-N calcium;4-methyl-2-oxopentanoic acid Chemical compound [Ca].CC(C)CC(=O)C(O)=O YJAKVPKJJMFDNW-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- GMBYRECIACINKD-GFAZQMFJSA-N dallergy Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1.C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)C2C3O2)(C)C)=CC=CC=C1 GMBYRECIACINKD-GFAZQMFJSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003621 hammer milling Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L29/00—Semiconductor devices adapted for rectifying, amplifying, oscillating or switching, or capacitors or resistors with at least one potential-jump barrier or surface barrier, e.g. PN junction depletion layer or carrier concentration layer; Details of semiconductor bodies or of electrodes thereof ; Multistep manufacturing processes therefor
- H01L29/40—Electrodes ; Multistep manufacturing processes therefor
- H01L29/401—Multistep manufacturing processes
- H01L29/4011—Multistep manufacturing processes for data storage electrodes
- H01L29/40114—Multistep manufacturing processes for data storage electrodes the electrodes comprising a conductor-insulator-conductor-insulator-semiconductor structure
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L29/00—Semiconductor devices adapted for rectifying, amplifying, oscillating or switching, or capacitors or resistors with at least one potential-jump barrier or surface barrier, e.g. PN junction depletion layer or carrier concentration layer; Details of semiconductor bodies or of electrodes thereof ; Multistep manufacturing processes therefor
- H01L29/40—Electrodes ; Multistep manufacturing processes therefor
- H01L29/41—Electrodes ; Multistep manufacturing processes therefor characterised by their shape, relative sizes or dispositions
- H01L29/423—Electrodes ; Multistep manufacturing processes therefor characterised by their shape, relative sizes or dispositions not carrying the current to be rectified, amplified or switched
- H01L29/42312—Gate electrodes for field effect devices
- H01L29/42316—Gate electrodes for field effect devices for field-effect transistors
- H01L29/4232—Gate electrodes for field effect devices for field-effect transistors with insulated gate
- H01L29/42324—Gate electrodes for transistors with a floating gate
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L29/00—Semiconductor devices adapted for rectifying, amplifying, oscillating or switching, or capacitors or resistors with at least one potential-jump barrier or surface barrier, e.g. PN junction depletion layer or carrier concentration layer; Details of semiconductor bodies or of electrodes thereof ; Multistep manufacturing processes therefor
- H01L29/66—Types of semiconductor device ; Multistep manufacturing processes therefor
- H01L29/68—Types of semiconductor device ; Multistep manufacturing processes therefor controllable by only the electric current supplied, or only the electric potential applied, to an electrode which does not carry the current to be rectified, amplified or switched
- H01L29/76—Unipolar devices, e.g. field effect transistors
- H01L29/772—Field effect transistors
- H01L29/78—Field effect transistors with field effect produced by an insulated gate
- H01L29/788—Field effect transistors with field effect produced by an insulated gate with floating gate
- H01L29/7881—Programmable transistors with only two possible levels of programmation
- H01L29/7884—Programmable transistors with only two possible levels of programmation charging by hot carrier injection
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L29/00—Semiconductor devices adapted for rectifying, amplifying, oscillating or switching, or capacitors or resistors with at least one potential-jump barrier or surface barrier, e.g. PN junction depletion layer or carrier concentration layer; Details of semiconductor bodies or of electrodes thereof ; Multistep manufacturing processes therefor
- H01L29/66—Types of semiconductor device ; Multistep manufacturing processes therefor
- H01L29/68—Types of semiconductor device ; Multistep manufacturing processes therefor controllable by only the electric current supplied, or only the electric potential applied, to an electrode which does not carry the current to be rectified, amplified or switched
- H01L29/76—Unipolar devices, e.g. field effect transistors
- H01L29/772—Field effect transistors
- H01L29/78—Field effect transistors with field effect produced by an insulated gate
- H01L29/788—Field effect transistors with field effect produced by an insulated gate with floating gate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Power Engineering (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Ceramic Engineering (AREA)
- Computer Hardware Design (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Manufacturing & Machinery (AREA)
- Neurology (AREA)
- Obesity (AREA)
Abstract
The present invention relates to a method for increasing the rate of bioavailability of orally administered supplemental dietary ingredients through the process of fine-milling to increase the rate of dissolution of the ingredients. The ingredients to be fine-milled are ingredients suitable for use in supplemental dietary compositions.
Description
- The present application is related to and claims benefit of priority to U.S. Provisional Application No. 60/776,325, entitled “Compositions and method for increasing the rate of bioavailability of supplemental dietary ingredients” filed Feb. 23, 2006, the disclosure of which is hereby fully incorporated by reference.
- The invention relates to the process of particle milling, micronization, for the purposes of increasing the rate of bioavailability following oral administration of components comprising supplemental dietary compositions. The compositions and methods promote increased rate of bioavailability by increasing the total surface area of poorly soluble particles, thereby increasing the rate of absorption.
- Poorly-soluble compounds are described as either sparingly soluble or insoluble in polar or non polar solvents depending on the hydrophilicity of lipophilicity of said compunds. Many compounds, particularly in the dietary supplement industry, fall into the class of low solubility. This not only presents a problem in terms of bioavailability but also in terms of reducing or preventing toxicity and irregular absorption in the intestinal tract (Shekunov B Y, Chattopadhyay P, Seitzinger J, Huff R. Nanoparticles of poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions. Pharm Res. January 2006; 23(1):196-204). Therefore, it is a challenge to make these compounds, which will be used in a biological system, e.g., orally ingested by a human, such that they will be more readily bioavailable. Various methods have been explored to achieve this in the pharmaceutical industry including chemical methods, physiological procedures, and pharmaceutical methods (Müller R H, Benita S, Böhm B (eds.). Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs, pp 15, 16, 20. Medpharm GmbH Scientific Publishers, Stuttgart, Germany. 1998). As such, it is advantageous to increase the rate of dissolution in a liquid medium or gastric juices as a method to increase bioavailability.
- The present invention relates to a method for increasing the rate of bioavailability of supplemental dietary ingredients in mammals. The rate of bioavailability is increased via a narrowing of particle size range and a concomitant reduction in the average particle size, improving the immediacy of absorption of said supplemental dietary ingredient. A further aspect of the present invention is to improve the consistency of dissolution, and thus the absorption of orally administered supplemental dietary ingredients.
- Definitions
- For the purposes of the present invention, the terms micronization, milling, particle-milling, and fine-milling are used interchangeably, wherein they refer to a technology, process and end-products involved in or leading to a narrowing of particle size range and a concomitant reduction in the average particle size. For the purposes of the present invention, acceptable milled-particle sizes are in the range of from about 1 nanometer to about 500 microns.
- Although it is understood by the inventors that dietary supplements from natural sources must inherently undergo a degree of processing prior to use, as used herein the terms ‘unprocessed’ or ‘regular’ refer the physical state of ingredients or compounds which have not been subjected to a micronization process.
- As used herein, the term ‘bioavailability’ refers to the amount of a substance available at a given site of physiological activity after administration. It is generally assumed that substances administered intravenously have a bioavailability of 100%. Bioavailability of a given substance is affected by a number of factors including but not limited to degradation and absorption of that substance. Orally administered substances are subject to excretion prior to complete absorption, thereby decreasing bioavailability as compared to other administration routes.
- As used herein, the term ‘molecule’ refers to the smallest size attainable of a given substance wherein the chemical properties of said substance are retained. It is understood that such molecules are themselves comprised of smaller atoms, however, the forces required and involved in reductions beyond the molecule scale are not the subject the of the present invention.
- As used herein, the term ‘particle’ refers to chunks or clumps of a substance of varying size wherein said chunks or clumps are comprised of varying numbers of molecules of a given substance. By way of example, the term ‘particle of ice’ is used to refer to a block of ice. Said particle of ice is comprised of several individual water molecules. The block of ice may be incrementally broken into smaller chunks or particles of ice still comprised of water molecules.
- As used herein, the term ‘solubility’ refers to the amount of or degree to which a substance or solute will dissolve within a given solvent. Several factors affect the solubility of a given substance. These factors include but are not limited to: specific properties of the solute and the solvent, polarity of the solute, the polarity of the solvent, the temperature and the pressure. The term ‘absolute solubility’, as used herein, refers to the solubility of a given substance under conditions in which time is not a factor, i.e. infinite time. It is understood that a substance may be in ‘suspension’ rather than solution but will appear to be in solution.
- As used herein, the term ‘dissolution’ refers to the process of a solute going into solution or solubilizing. Dissolution is dependent upon several factors including but not limited to: temperature, agitation and surface area of a given particle.
- It is herein understood that, due to the relationship between solubility and dissolution, the amount of a substance in solution at any given time is dependent upon both dissolution and solubility. Furthermore, it is understood by way of extension that increasing the rate of dissolution of a given substance may act to reduce the time to dissolution of a given solute or substance in a given solvent. However, the absolute solubility of said solute does not increase with infinite time. Thus, increasing the rate of dissolution of a substance will increase the amount of said substance in solution at earlier points in time, thus increasing the rate of bioavailability of said substance at earlier times upon oral administration.
- As it relates to this invention, micronization techniques are employed to increase the rate of bioavailability of said poorly soluble supplemental dietary ingredients. The increase in the rate of bioavailability will allow better and quicker compound transfer to the systemic parts of the body following ingestion, and thus increase efficacy of the compositions comprising such supplemental dietary ingredients.
- Micronization is a technique which has been used as a method of sizing solid compounds to fine powders. Following a micronization process, said poorly soluble compounds are transformed into fine powders which can then be transformed into suitable, stable and patient-compliant dosage forms. These forms, for the purposes of the present invention are derived for oral administration.
- Micronization-technique treated poorly-soluble compounds or dietary supplement ingredients are preferred in the present invention in that they offer an advantage over larger forms of poorly soluble compounds—following micronization, compounds have higher surface area to volume ratio. This provides for, as compared to physically coarse compounds, an ultrafine micronized powder that has a significantly increased total surface area. Mathematically, cross-sectional surface area increases with the square of the radius, while volume increases with the cube of the radius. Therefore, as a particle becomes smaller, the volume of the particle decreases at a faster rate than the surface area leading to an increase in the ratio of surface area to volume. By way of theoretical calculations, decreasing the size of a particle can increase its rate of dissolution via increasing the surface area to volume ratio. In the case of solubility, this increase in relative surface area allows for greater interaction with solvent.
- For example, consider 1 cm3 of coarse compound occupying a virtually spherical volume (V), for demonstration purposes, a single particle of any given substance. The surface area (SA) of this 1 cm3 particle is calculated using Formula I to solve for the radius (r). This value for r is used to calculate SA with Formula II:
V=(4/3)pi r 3 (I)
SA=4pi r 2 (II)
Therefore, a particle with V of 1 cm3 has SA of approximately 4.8 cm2. If this substance were milled to several particles each having a V of 0.5 mm3, each particle would have SA of approximately 0.03 cm2. In this example, the volume of a single 1 cm3 particle could contain 2000 of the particles fine-milled to a size of 0.5 mm3 with a total SA of 2000 particles×0.03 cm2 per particle which equals 60 cm3 and therefore corresponds to a 60-fold increase in total SA. This increase in total SA would allow for greater access of solvent molecules to solute molecules, thus leading to a greater rate of dissolution. - Micronization or particle-milling for the purposes of the present invention is preformed by a variety of methods. Dry milling or nanosuspensions are often made by air jet milling and wet milling in pearl mills and rotor-stator mills as commonly known in the art as part of the micronization process.
- Methods of milling particles can also be those such as hammer mills, cryogenic hammer mills, fluid and air jet milling, jaw crushing, and high-pressure dispersion milling. These are methods of medialess milling. Hammer milling produces particles of typically 30-500 microns. At ambient temperatures, rotating hammers which strike the particles repeatedly reduce the particle size to a point where they can pass through a screen having a given mesh size. If required, the process can also be done at lower temperatures in cases where a reduced temperature is required to fracture a given particle.
- During the process of jet milling, particles are suspended in flowing streams of air where they are targeted at either themselves or a stationary target. This results in a fine grind with a particle size of typically 1-10 microns being produced.
- A further type of medialess milling which may be employed in the present invention is high pressure dispersion milling in which dispersions are pressurized to 10,000-50,000 psi. At this point, the pressure is rapidly released. This release in pressure causes cavitation and grinding. Particles of 0.5 to 1 micron are typically produced via this method (The Aveka Group, Specialists in Particle Processing. Grinding and Classification. www.aveka.com/grinding_and_classification.htm).
- In the process known as media milling, balls, pebbles or other media such as sand are added in with material to be ground in order to reduce particle size. The collisions of the media with material to be ground results in the fracture of the large particles into smaller such particles. Using media milling, particles can be milled to average sizes of 0.1 micron with relative ease. Through control of the grinding time and force with which the material is ground, virtually any particle size can be obtained. Media mill can be used with or without any liquids additives, although water or other solvents are commonly used to produce the finest particle.
- Until recently, the actual quantitation of milling in terms of size distribution and the effects of process variables have been complicated. Mathematical models predicting the size and size distribution of milled particles have been developed (Pierre Chapelle, Nicholas Christakis, Hadi Abou-Chakra, Ian Bridle, M. S. A. Bradley, Mayur Patel, Mark Cross. Computational model for prediction of particle degradation during dilute phase pneumatic conveying: Modelling of dilute phase pneumatic conveying. Advanced Powder Technology, 2004 Vol 15, pp. 31-50) and deemed valid by the demonstrated agreement with laboratory results. For jet milling for example, it is now known how variables such as feed rate, angle of inlet nozzle and air flow rate affect the process of micronization. This allows for a much greater control over resultant particle size with narrower size distribution.
- Examples of mills and techniques for milling particles for the purposes of size reduction are disclosed in e.g. U.S. Pat. Nos. 4,006,025, 4,294,916, 4,294,917, 4,490,654 and 4,950,586 and 4,927,744.
- U.S. Pat. No. 6,604,698, fully incorporated herein by reference, discloses a process for preparing a dispersion of solid particles of a milled substrate in a fluid carrier comprising the use of both large and small milling media in a media mill, separating the produced fine particles from the milling media by the use of a screen in the fluid carrier. The product then remains in the fluid carrier or can be removed via the evaporation of the fluid carrier.
- U.S. Pat. No. 6,634,576, fully incorporated herein by reference, discloses a process for milling a solid substrate in the milling chamber of a dispersion or media mill in the presence of two or more compositions of milling media bodies, wherein the milling media bodies contribute to the grinding of the solid substrate and wherein at least one composition of media bodies provides fragments of milling media bodies that are retained with the milled substrate particles in a synergistic commixture produced in the milling process.
- For the purposes of various embodiments herein disclosed, but not limited to existing embodiments, the process of micronization is referred to as fine-milling. As used herein, fine-milling is a process employing current micronization techniques whereby the size of a particle is reduced to a range between 2 to 50 microns. Preferably, jet milling is used to produce fine-milled particles involving the steps of feeding the material into a hopper. The material to be fine-milled is then gravity fed into a pipe which employs an auger to propagate the material into the jet mill. Utilizing two opposing forces; free vortex resulting from centrifugal force imparted on the particles by the nozzles and drag force, created by the gas-flow as it spirals towards the centre of the mill, the particles are reduced in size as the nozzles are arranged tangentially in the peripheral wall of the grinding chamber. As the particle size is reduced, said particles are drawn to the centre of the mill where they leave the mill via a pneumatic conveyor and are collected in a bag filter. The gas is vented to waste.
- Therefore, the present invention is directed at the process of fine-milling of supplemental dietary ingredients leading to a method of increasing the rate of bioavailability following oral administration. The increased rate of dissolution ensures an increased number of molecules in solution in a liquid supplemental dietary composition or gastric juices, thereby improving bioavailability. Since more molecules will be available in a readily absorbable state, and thus bio-absorption prior to excretion for an individual's body, the method of the present invention thereby improves bioavailability.
- Moreover, with respect to the small particle size of fine-milled products, there may be an improved taste, flavor-enhancement, texture and palatably of compositions comprising poorly-soluble compounds which have been fine-milled owing to the improved rate of dissolution.
- Experiments relating to fine-milling and bioavailability were undertaken by the inventors. Outlines and the result of said experiments are given below.
- In order to determine the effect of fine-milling on the dissolution rate, initial testing was performed to examine the rate of dissolution of common supplemental dietary ingredients. For the purposes of this disclosure, the term “regular” as used herein makes reference to non-fine-milled particles.
- Experimental Procedure:
- 100 mL of water was placed into a 250 mL beaker and a magnetic stirrer bar was added to the beaker. The beaker was then placed on a magnetic stirrer was set to constant speed. Increments of 2 g of regular ingredients were quickly added wherein the next increment was added after the previous increment visually appeared to dissolve until the mixture appeared saturated. The time required to dissolve was estimated by visual inspection. Equal amounts of the fine-milled ingredients were then added to the water and the time required to dissolve was estimated by visual inspection. The supplemental dietary ingredients used were Zinc Acetate, L-Arginine base, Creatine Ethyl Ester and Creatine Monohydrate.
- Results
TABLE 1 Amount Time taken Powder Added to dissolve Sample Name Type (g) (min) Zinc Acetate Regular 18 >10 Fine-milled 18 <10 Arginine Regular 16 >10 Fine-milled 16 <10 Creatine Ethyl Regular 22 >10 Ester Fine-milled 22 <10 Creatine Regular 2 <5 Monohydrate Fine-milled 2 <5 - Table 1 presents the observations made examining the time to dissolve for non-milled and fine-milled ingredients. In all cases, the fine-milled ingredients dissolved faster then the regular ingredients with the exception of Creatine Monohydrate. The Creatine Monohydrate sample appeared to dissolved at the same rate in both the fine-milled and regular formats.
- Discussion:
- In three of the four cases examined, the fine-milled ingredients took less time to dissolve according to visual inspection. For Zinc Acetate, Arginine and Creatine Ethyl Ester the fine-milled samples dissolved within 10 minutes, whereas the non-milled versions of these ingredients all required greater than 10 minutes. Creatine Monohydrate, which is known to be of relatively low solubility, did not display a difference dependent on particle size.
- A second experiment relating to fine-milling and potential increase in bioavailability was conducted. In order to test the capacity of fine-milling to improve the rate bioavailability of substances, a simple test was performed. The test was conceived to mimic various elements involved in the processes of oral administration of a nutritional supplement. The key parameters involved were rate of dissolution and solubility, as it is understood that an ingested nutrient must be dissolved or reduced to a bio-transportable size in order to be utilized biochemically by the body.
- Digestion converts complex foods into nutrients useable by cells. As such, digestion can be divided into distinct processes including ingestion, mechanical digestion, chemical digestion and absorption. Orally consumed substances are first broken down in the mouth by a combination of physical forces (chewing) and salivary enzymes. In the stomach, substances are further broken down by churning and mixing with more enzymes and acid. Partially digested substances then pass to the small intestine where more enzymes complete digestion. In the case of many supplemental dietary ingredients enzymatic digestion does not occur, therefore another method of bioavailability must occur. In the present invention, bioavailability of these substances is improved by fine-milling. The increase in the dissolution rate, it is understood by the inventors, to lead to and increase in bioavailability by increasing the likelihood that a given molecule is absorbed by the body of an individual prior to excretion. In the case of poorly-soluble substances, the substance may be excreted before it is absorbed if it is not fine-milled, thereby decreasing bioavailability. Absorption of digested substances begins in the stomach and occurs mainly in the small intestine and is facilitated by diffusion and active transport. Water is typically an important component of these processes as the enzymatic reactions often require that substances be in solution, e.g., dissolved.
- Experimental Procedure
- The rates of dissolution and solubility of regular common nutritional supplements were compared to fine-milled versions within a fixed time. The substances tested were whey protein concentrate, creatine monohydrate, L-arginine, and glycine-L-arginine-alpha-ketoisocaproic acid calcium. 100 mL of water was added to a 250 mL beaker and a magnetic stirring bar was placed in the beaker. The beaker was placed on a magnetic stirrer and stirred with low speed. 1 g of a given supplemental dietary ingredient powder was added incrementally to the beaker with the stirring speed constant until the solution visually appeared saturated. The solution was filtered by gravity through a pre-weighed filter paper (Whatman 41, particle retention 20-25 μm). The filter paper was allowed to dry completely and weighed to measure the amount of substance remaining on the filter paper.
- Results
TABLE 2 Dry Max Powder Approx. Amount On Molecular Sample Powder Dissolved Filter Fold Mass Name Type (g) (g) Change (g/mol) Whey Protein Regular 12 0.79 NA Fine-milled 12 0.15 5.3 Creatine Regular 2 0.19 149 Monohydrate Fine-milled 2 0.01 19.0 glycine-L- Regular 18 0.42 418 arginine- Fine-milled 18 0.31 1.4 alpha- ketoisocaproic acid calcium Arginine Regular 16 0.36 174 Fine-milled 16 0.25 1.4 - Table 2 presents the results of the solubility test designed to mimic bioavailability to compare regular substances to their fine-milled counterparts. The ‘Fold Change’ represents the change in the amount of substance unable to pass through the filter as calculated by the amount of unfiltered regular substance divided by the amount of unfiltered fine-milled substance and represents the potential theoretical improvement in bioavailability. The approximate molecular weight is also shown for comparison.
- Discussion
- In analogy to digestion, the experimental test system employed herein assesses bioavailability in relation to rate of dissolution and solubility on the premise that undissolved substances will be excreted from the body of an individual and not be absorbed. The mixing of the samples with a magnetic stir bar is analogous to mechanical digestion in the mouth and stomach. The passage of the samples through the filter paper is likewise analogous to the absorption of nutrients through cell membranes. In both cases (digestion and the current experimental test system), the rate of dissolution and solubility are factors. It is important to understand that molecules in solution are individual molecules. Those substances in powder form, and by extension substances in solid forms derived from powdered substances such as tablets and capsules, typically must be dissolved before they can effectively pass through a membrane. Furthermore, it is important to understand that substances in powder form are present in chunks or clumps of molecules with a distribution of particle sizes. The goal of micronization or milling for the purposes of the present invention is to reduce the average particle size, ideally to the smallest size attainable, e.g., a single molecule. It is understood that the absolute solubility is not affected by reduced particle size whereas the rate of dissolution is drastically increased or improved by a fine-milling process.
- Therefore, sample material remaining on the filter paper represents two non-mutually exclusive cases. One case is that soluble molecules are too large to pass through the pores of the filter. In this case, none of the solubilized molecules will pass through the pores of the filter paper. The second case is that the material represents insoluble or yet-undissolved sample material present as particles that are too large to pass through the pores of the filter. It is understood that insoluble particles comprised of numerous single molecules in suspension may be deemed to be in solution by the naked eye under visual inspection, however, they are in fact not actually in solution.
- In all cases the fine-milled samples passed through the filter paper more readily and effectively than did the regular samples, i.e. more of the regular samples remained on the filter than the fine-milled samples. It was also observed that in all cases the regular samples took more time to filter than the fine-milled samples (data not shown). These data suggest that the dissolution rate of the substances was increased by fine-milling via decreasing average particle size.
- It is interesting to note that the ‘Fold Change’ appears to be correlated to two parameters. The substance that was least soluble (creatine) showed the most significant improvement (19-fold), while the most soluble (glycine-L-arginine-alpha-ketoisocaproic acid calcium and L-arginine) showed the least improvement (1.4-fold). Also, the molecular weight may contribute to the efficacy afforded by fine-milling as evidenced by the lowest molecular weight substance (creatine) showing the largest improvement. It should be noted that the molecular weight of the whey protein concentrate is not listed as it is a distribution of multiple protein fractions but the average is most likely significantly larger than the other substances tested and does not therefore likely follow this second potential correlate. However, the theoretical smallest size of a protein particle is the size of an individual amino acid e.g. L-arginine, which constitutes the protein. Therefore, significant improvement for whey protein (5.3-fold) is not surprising.
- Further to improving bioavailability, it is understood by the inventors that increased solubility resulting from fine-milling will lead to improvements in characteristics in which solubility and reduced particle size likely play a role. For example, a fine-milled ingredient used in the formulation of a nutritional bar will be less course in texture and more palatable than a non-fine-milled ingredient. Likewise, a fine-milled ingredient used in the formulation of a nutritional beverage will be less ‘gritty’ due to reduced particle size and increased rate of dissolution.
- In order to expand on the results of the aforenoted experiments, a kinetic experiment was conducted to examine the change in the dissolution rate over short time periods.
- Experimental Procedure
- Following the same method as immediately above experiment, the solubility of non-milled or regular Creatine monohydrate was compared to that of fine-milled Creatine monohydrate. 1 g of sample was added to 50 mL water in a flask with a magnetic stir bar on a stirrer set at constant speed. Separate samples were filtered at 1 and 5 minutes. The pre-weighed filter papers (Whateman 41, particle retention 20-25 μm) were allowed to dry and the amount of sample remaining on the filter paper was determined.
- Results
- 1-Minute Interval:
- Regular Creatine monohydrate
-
- weight of empty filter paper=2.30 g
- weight of filter paper after=2.62 g
- weight of unfiltered sample=0.32 g
- time to filter=2 minutes
- Fine-Milled Creatine Monohydrate
-
- weight of empty filter paper=2.26 g
- weight of filter paper after=2.59 g
- weight of unfiltered sample=0.33 g
- time to filter=3.5 to 4 minutes
5-Minute Interval:
- Regular Creatine Monohydrate
-
- weight of empty filter paper=2.29 g
- weight of filter paper after=2.69 g
- weight of unfiltered sample=0.40 g
- time to filter=1 to 1.5 minutes
- Fine-Milled Creatine Monohydrate
-
- weight of empty filter paper=2.22 g
- weight of filter paper after=2.49 g
- weight of unfiltered sample=0.27 g
- time to filter=2 to 2.5 minutes
Discussion
- At the 1-minute interval, essentially equal amounts of regular and fine-milled creatine were retained by the filter paper (0.33 g and 0.32 g). However, at the 5-minute interval, more of the regular creatine was retained by the filter paper than fine-milled creatine (0.40 g versus 0.27 g). This suggests that more of the fine-milled creatine was able to pass through the filter paper after 5 minutes i.e. more was in solution. The time to filter was consistently longer for the fine-milled samples. This may be explained by the ability of the smaller fine-milled particles to become entrapped within the pores of the filter paper, thus slowing the rate of solvent passage. It is commonly known in the area of column chromatography that molecules too large to enter the pores of the separation matrix do not usually impede the rate of flow of solvent, while molecules small enough to enter the porous matrix become trapped and may impede the solvent flow rate.
- In the present invention as a first example embodiment of a supplemental dietary composition that comprises the use of a ketoacid in combination with one or more monobasic amino acids as disclosed in U.S. application Ser. No. 11/595,170 incorporated herein in its entirety by reference, is provided. With respect to the instant composition, poorly-soluble monobasic, dibasic, and tribasic amino acids and ketoacid are treated fine-milled to increase solubility and thus bioavailability. An embodiment comprising the present invention is set forth in greater detail in Example 1.
- Furthermore, the present disclosure provides a second example embodiment of a supplemental dietary composition that comprises the use of a ketoacid in combination with one or more cationic or dibasic amino acids as disclosed in U.S. Pat. No. 6,100,287 incorporated herein in its entirety by reference wherein at least one of the components is fine-milled. With respect to this composition, cationic and dibasic amino acids and ketoacids are fine-milled to increase solubility, and thus bioavailability. An embodiment comprising present invention is set forth in greater detail in Example 2.
- Additionally, the present disclosure provides a third example embodiment of a supplemental dietary composition that comprises the use of Creatine-Ethyl Ester, Creatine Alpha-ketoglutarate and Alpha-lipoic acid as disclosed in U.S. application Ser. No. 11/399,885 incorporated herein in its entirety by reference. With respect to this composition, the components which comprise this example are fine-milled to increase solubility and thus bioavailability. An embodiment comprising present invention is set forth in greater detail in Example 3.
- An aspect of the present invention is the inclusion of fine-milled supplemental dietary ingredients as part of a greater composition comprising like and additional ingredients. As part of the greater composition the fine-milled ingredients may be present in ratios from about 50:1 to about 4:1.
- Although the following examples illustrate the practice of the present invention in three of its embodiments the examples should not be construed as limiting the scope of the invention. Other embodiments will be apparent to one skilled in the art from consideration of the specification and the following examples.
- In Powdered Form
- A dietary supplement comprising the following ingredients per serving is prepared for consumption one time per day per individual:
- about 2.0 ng of fine-milled Glycine, about 2.0 g of regular Glycine, about 5.0 ng of fine-milled L-Arginine, about 5.0 g of regular L-Arginine, about 3.0 ng of fine-milled Calcium-KIC, about 3.0 g of regular Calcium-KIC, about 2.0 g of Maltodextrin, about 1.5 g of Citric Acid, about 80 g of Dextrose, about 0.5 g of Sodium Citrate, about 0.3 g of Sodium Gluconate, about 0.4 g of Polyvinylyrolidone, about 0.1 g of Modified Food Starch, about 0.4 g of Syurp Solids, about 0.03 g of Gum Acacia, about 0.05 g of Silicon Dioxide, about 0.027 g of Acesulfame-Potassium, and about 0.01 g FD&C Red #40.
- Preferably, the nutritional composition is consumed in accordance with the following directions:
- Directions: As a dietary supplement, take one serving (35 g) of product before a high-intensity workout. Mix in a shaker cup with 8 oz. of water. Serve immediately. Consume ten 8 oz. glasses of water daily for general good health.
- In Caplet Form
- A dietary supplement comprising the following ingredients per serving is prepared for consumption one time per day per individual:
- about 2.0 ng of fine-milled Glycine, about 2.0 g of regular Glycine, about 5.0 ng of fine-milled L-Arginine, about 5.0 g of regular L-Arginine, about 3.0 ng of fine-milled Calcium-KIC, about 3.0 g of regular Calcium-KIC, about 1.5 g Microcrystalline Cellulose, about 0.88 g Hydroxypropyl Cellulose, about 0.6 g Coating [Partially Hydrolyzed Polyvinyl Alcohol, Polyethylene Glycol, Hydroxypropyl Cellulose, Titanium Dioxide, Talc, Soy Lecithin, Polysorbate 80, Colourings], about 0.176 g Croscarmellose Sodium, about 0.176 g Stearic Acid, about 0.088 g Magnesium Stearate, about 0.044 g Silica and about 0.43 mg Acesulfame-potassium.
- Preferably, the nutritional composition is consumed in accordance with the following directions:
- Directions: As a dietary supplement, take one serving (8 caplets) per day before a high-intensity workout. Do not exceed one serving in a 24-hour period. Consume ten 8 oz. glasses of water daily for general good health.
- A dietary supplement comprising the following ingredients per serving is prepared for consumption one to four times per day per individual:
- about 7.5 g Leucine, about 0.0004 g fine-milled Leucine, about 0.05 g Calcium-KIC, about 0.45 g Hydroxyprpoyl Cellulose, about 1.75 g Microcrystalline Cellulose, about 0.18 g Croscarmellose Sodium, about 0.03 g Calcium Carbonate, about 0.12 g Vegetable Stearine, about 0.06 g Magnesium Stearate, about 0.06 g Silica, about 0.03 g Magnesium Silicate, about 0.306 g Coating [Polyvinyl Alcohol, Polyethylene Glycol, Talc, Titanium Dioxide, Riboflavin, Soy Lecithin, Polysorbate 80, Hydroxypropyl methylcellulose, Colorings], about 0.001 g Lysine Ketoisocaproic Acid and about 0.0004 g Sweeteners.
- Preferably, the nutritional composition is consumed in accordance with the following directions:
- Directions: As a dietary supplement, take 1 serving (6 caplets) first thing in the morning. On workout days, take 1 serving immediately before your workout. For extreme results, take twice a day. Consume ten 8 oz. glasses of water daily for general good health.
- A dietary supplement comprising the following ingredients per serving is prepared for consumption one to four times per day per individual:
- about 2.0 g regular Creatine-Ethyl Ester HCl, about 0.001 g fine-milled Creatine-Ethyl Ester HCl, about 0.1 g Creatine Alpha-ketoglutarate and about 0.1 g Alpha-lipoic Acid.
- Preferably, the nutritional composition is consumed in accordance with the following directions:
- Directions: As a dietary supplement, take two servings per day, e.g., one serving (2 caplets) in the morning and one serving (2 caplets) in the afternoon. Consume 10 8 oz. Glasses of water daily. To maximize results, use in conjunction with weight training.
Claims (38)
1. A method for increasing the rate of bioavailability of a supplemental dietary ingredient in a mammal, the method comprising the step of:
fine-milling said ingredient such that, upon administration of said fine-milled ingredient to said mammal, the immediacy of absorption of said supplemental dietary ingredient in said mammal is improved as compared to an immediacy of absorption of said ingredient when said ingredient is in a regular form.
2. The method of claim 1 , whereby the improved immediacy of absorption is the result of an increased rate of dissolution of said supplemental dietary ingredient in said mammal, thereby increasing the rate of bioavailability of said supplemental dietary ingredient.
3. The method of claim 1 , wherein said fine-milled supplemental dietary ingredient is suitable to be orally administered.
4. The method of claim 1 , further comprising the step of:
providing said fine-milled supplemental dietary ingredient in a composition, the composition including said ingredient in a regular form.
5. The method of claim 4 , wherein the ratio of regular form to fine-milled form of said supplemental dietary ingredient is from about 5:1 to about 10,000:1.
6. The method of claim 1 , wherein said fine-milled particles have an average size range of between from about 2 to about 50 microns.
7. A method for improving the consistency of the rate of digestive absorption of a supplemental dietary ingredient in a mammal, the method comprising the step of:
fine-milling said ingredient so as to improve a uniformity of particles sizes of said ingredient, such that, upon administration of said fine-milled ingredient to said mammal, the consistency of the rate of digestive absorption is improved as compared to a rate of digestive absorption of said ingredient in regular form due to said improved uniformity of the particle size.
8. The method of claim 7 , wherein said fine-milled particles have an average size range of between about 2 to about 50 microns.
9. A method for manufacturing a supplemental dietary composition suitable for ingestion by a mammal, the method comprising the step of:
providing in the supplemental dietary composition an ingredient, the ingredient being fine-milled such that, upon administration of said fine-milled ingredient to said mammal, a rate of bioavailability of said ingredient is improved as compared to a rate of bioavailability of said ingredient when said ingredient is in a regular form.
10. The method of claim 9 , wherein said supplemental dietary composition having said ingredient is suitable to be ingested orally.
11. The method of claim 9 , further comprising the step of providing in the supplemental dietary composition said ingredient in a regular form.
12. The method of claim 11 , wherein the ratio of regular form to fine-milled form of said ingredient is from about 5:1 to about 10,000:1.
13. The method of claim 9 , wherein said fine-milled ingredient includes particles having an average size range between about 2 and about 50 microns.
14. A method for manufacturing a supplemental dietary composition suitable for ingestion by a mammal, the method comprising the step of:
providing in the supplemental dietary composition an ingredient, the ingredient being fine-milled such that, upon administration of said fine-milled ingredient to said mammal, an immediacy of absorption of said ingredient is improved as compared to an immediacy of absorption of said ingredient when said ingredient is in a regular form.
15. The method of claim 14 , wherein said supplemental dietary composition having said ingredient is suitable to be ingested orally.
16. The method of claim 14 , further comprising the step of providing in the supplemental dietary composition said ingredient in a regular form.
17. The method of claim 16 , wherein the ratio of regular form to fine-milled form of said ingredient is from about 5:1 to about 10,000:1.
18. The method of claim 14 , wherein said fine-milled ingredient includes particles having an average size range between about 2 and about 50 microns.
19. A method for manufacturing a supplemental dietary composition suitable for ingestion by a mammal, the method comprising the step of:
providing in the supplemental dietary composition an ingredient, the ingredient being fine-milled such that, upon administration of said fine-milled ingredient to said mammal, a rate of dissolution of said ingredient is improved as compared to a rate of dissolution of said ingredient when said ingredient is in a regular form.
20. The method of claim 19 , wherein said supplemental dietary composition having said ingredient is suitable to be ingested orally.
21. The method of claim 19 , further comprising the step of providing in the supplemental dietary composition said ingredient in a regular form.
22. The method of claim 21 , wherein the ratio of regular form to fine-milled form of said ingredient is from about 5:1 to about 10,000:1.
23. The method of claim 19 , wherein said fine-milled ingredient includes particles having an average size range between about 2 and about 50 microns.
24. A method for manufacturing a supplemental dietary composition suitable for ingestion by a mammal, the method comprising the step of:
providing in the supplemental dietary composition an ingredient, the ingredient being fine-milled such that, upon administration of said fine-milled ingredient to said mammal, a consistency of the rate of digestive absorption of the ingredient is improved as compared to a consistency of the rate of digestive absorption of the ingredient when said ingredient is in a regular form.
25. The method of claim 24 , wherein said supplemental dietary composition having said ingredient is suitable to be ingested orally.
26. The method of claim 24 , further comprising the step of providing in the supplemental dietary composition said ingredient in a regular form.
27. The method of claim 26 , wherein the ratio of regular form to fine-milled form of said ingredient is from about 5:1 to about 10,000:1.
28. The method of claim 24 , wherein said fine-milled ingredient includes particles having an average size range between about 2 and about 50 microns.
29. A method for manufacturing a supplemental dietary composition suitable for ingestion by a mammal, the method comprising the step of:
providing in the supplemental dietary composition an ingredient, the ingredient being fine-milled such that a uniformity of particles sizes of said ingredient is improved as compared to a uniformity of particles sizes of said ingredient when said ingredient is in a regular form.
30. The method of claim 29 , wherein said supplemental dietary composition having said ingredient is suitable to be ingested orally.
31. The method of claim 29 , further comprising the step of providing in the supplemental dietary composition said ingredient in a regular form.
32. The method of claim 31 , wherein the ratio of regular form to fine-milled form of said ingredient is from about 5:1 to about 10,000:1.
33. The method of claim 29 , wherein said fine-milled ingredient includes particles having an average size range between about 2 and about 50 microns.
34. A supplemental dietary composition suitable for ingestion by a mammal, comprising:
a fine-milled ingredient which, upon administration of said fine-milled ingredient to said mammal, has a rate of bioavailability that is improved as compared to a rate of bioavailability of said ingredient when said ingredient is in a regular form.
35. The method of claim 34 , wherein said supplemental dietary composition having said ingredient is suitable to be ingested orally.
36. The method of claim 34 , further comprising the step of providing in the supplemental dietary composition said ingredient in a regular form.
37. The method of claim 36 , wherein the ratio of regular form to fine-milled form of said ingredient is from about 5:1 to about 10,000:1.
38. The method of claim 34 , wherein said fine-milled ingredient includes particles having an average size range between about 2 and about 50 microns.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/709,526 US20070202166A1 (en) | 2006-02-23 | 2007-02-21 | Method for increasing the rate and consistency of bioavailability of supplemental dietary ingredients |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77632506P | 2006-02-23 | 2006-02-23 | |
US11/709,526 US20070202166A1 (en) | 2006-02-23 | 2007-02-21 | Method for increasing the rate and consistency of bioavailability of supplemental dietary ingredients |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070202166A1 true US20070202166A1 (en) | 2007-08-30 |
Family
ID=38433828
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/486,866 Active US7476405B2 (en) | 2006-02-23 | 2006-07-14 | Compositions and methods for the induction and maintenance of quality sleep |
US11/505,779 Expired - Fee Related US7794749B2 (en) | 2006-02-23 | 2006-08-16 | Rapidly dissolving solid oral dosage form for delivery of composition for increasing nitric oxide activity |
US11/522,266 Expired - Fee Related US7749547B2 (en) | 2006-02-23 | 2006-09-14 | Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise |
US11/709,525 Abandoned US20070202165A1 (en) | 2006-02-23 | 2007-02-21 | Method for a supplemental dietary composition having a multi-phase dissolution profile |
US11/709,526 Abandoned US20070202166A1 (en) | 2006-02-23 | 2007-02-21 | Method for increasing the rate and consistency of bioavailability of supplemental dietary ingredients |
US11/821,229 Expired - Fee Related US7906154B2 (en) | 2006-02-23 | 2007-06-21 | Compositions and methods for the induction and maintenance of quality sleep |
US12/206,892 Expired - Fee Related US7914826B2 (en) | 2006-02-23 | 2008-09-09 | Method for promoting sleep |
US12/291,482 Abandoned US20090142410A1 (en) | 2006-02-23 | 2008-11-10 | Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/486,866 Active US7476405B2 (en) | 2006-02-23 | 2006-07-14 | Compositions and methods for the induction and maintenance of quality sleep |
US11/505,779 Expired - Fee Related US7794749B2 (en) | 2006-02-23 | 2006-08-16 | Rapidly dissolving solid oral dosage form for delivery of composition for increasing nitric oxide activity |
US11/522,266 Expired - Fee Related US7749547B2 (en) | 2006-02-23 | 2006-09-14 | Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise |
US11/709,525 Abandoned US20070202165A1 (en) | 2006-02-23 | 2007-02-21 | Method for a supplemental dietary composition having a multi-phase dissolution profile |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/821,229 Expired - Fee Related US7906154B2 (en) | 2006-02-23 | 2007-06-21 | Compositions and methods for the induction and maintenance of quality sleep |
US12/206,892 Expired - Fee Related US7914826B2 (en) | 2006-02-23 | 2008-09-09 | Method for promoting sleep |
US12/291,482 Abandoned US20090142410A1 (en) | 2006-02-23 | 2008-11-10 | Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise |
Country Status (7)
Country | Link |
---|---|
US (8) | US7476405B2 (en) |
EP (2) | EP1991241A4 (en) |
JP (1) | JP2009527504A (en) |
AU (2) | AU2006338839A1 (en) |
CA (3) | CA2642761A1 (en) |
WO (5) | WO2007095716A1 (en) |
ZA (1) | ZA200807489B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009094750A1 (en) * | 2008-01-31 | 2009-08-06 | Northern Innovations And Formulations Corp. | Fast dissolution amino acid composition |
CN104582686A (en) * | 2012-08-21 | 2015-04-29 | 利普生物药剂公司 | Trans-clomiphene formulations and uses thereof |
US9675564B2 (en) | 2011-12-02 | 2017-06-13 | Asoltech S.R.L. | Composition based on ubidecarenone |
US9687458B2 (en) | 2012-11-02 | 2017-06-27 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
US9968567B2 (en) | 2014-11-14 | 2018-05-15 | Asoltech S.R.L. | Composition based on COQ10 |
US9981906B2 (en) | 2011-08-04 | 2018-05-29 | Repros Therapeutics Inc. | Trans-clomiphene metabolites and uses thereof |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5214464B2 (en) | 2005-12-28 | 2013-06-19 | アドバンスド バイオニュートリション コーポレーション | Delivery medium for probiotic bacteria, in the form of glass, comprising a dry matrix of polysaccharides, saccharides and polyols and method for producing the same |
US20080254121A1 (en) * | 2007-04-10 | 2008-10-16 | Iomedix Sleep International Srl | Multi-layer melatonin composition |
JP5714227B2 (en) * | 2007-05-31 | 2015-05-07 | サントリーホールディングス株式会社 | Anti-fatigue agent and oral composition containing andrographolide as active ingredient |
WO2009047004A1 (en) * | 2007-10-10 | 2009-04-16 | Daniel Farrington | A homeopathic complex |
US20090156634A1 (en) * | 2007-12-12 | 2009-06-18 | Iovate T. & P. Inc. | Tropane alkaloids and trigonelline combinations and methods for administering the same |
US20090304602A1 (en) * | 2008-06-06 | 2009-12-10 | Tuchinsky David B | Nutritional supplement |
WO2009147229A1 (en) * | 2008-06-06 | 2009-12-10 | Phytolab Gmbh & Co. Kg | Synergistic enhancement of cellular ergogenic nutrient uptake, like creatine or carnitine, with tarragon |
CA2732892C (en) * | 2008-08-15 | 2020-12-15 | Forest Laboratories Holdings Limited | Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration |
US20100124587A1 (en) * | 2008-11-17 | 2010-05-20 | Heuer Marvin A | Creatine-containing vitamin and mineral composition |
JP5558016B2 (en) * | 2009-03-17 | 2014-07-23 | 株式会社 資生堂 | Circadian rhythm regulator |
US20100256215A1 (en) * | 2009-04-02 | 2010-10-07 | Silver Eagle Labs Nv, Llc | Menthol-Melatonin Dissolving Film |
US20100256197A1 (en) * | 2009-04-02 | 2010-10-07 | Silver Eagle Labs Nv, Llc | Nicotine Dissolving Film With Or Without Menthol |
CN102459568A (en) | 2009-05-26 | 2012-05-16 | 先进生物营养公司 | Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making |
US8748573B2 (en) * | 2009-08-06 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
US9445622B2 (en) * | 2009-12-21 | 2016-09-20 | Glanbia Nutritionals (Ireland) Ltd. | Compositions and methods for improving creatine solubility and stability |
EP2533791B1 (en) * | 2009-12-21 | 2017-01-25 | Glanbia Nutritionals (Ireland) Ltd. | Leucine/peptide composition and method of formulation |
PL2529004T3 (en) | 2010-01-28 | 2017-12-29 | Advanced Bionutrition Corporation | Dry glassy composition comprising a bioactive material |
US9504750B2 (en) | 2010-01-28 | 2016-11-29 | Advanced Bionutrition Corporation | Stabilizing composition for biological materials |
WO2011098394A2 (en) * | 2010-02-09 | 2011-08-18 | Reiner Rittinghausen | Composition for the treatment and prevention of anxiety disorders and dyssomnia |
AU2011218009B2 (en) | 2010-02-17 | 2016-11-03 | Ironwood Pharmaceuticals, Inc | Treatments for gastrointestinal disorders |
US8828453B2 (en) * | 2010-04-29 | 2014-09-09 | Betul Hatipoglu | Herbal-based compositions for alleviating symptoms associated with autism |
WO2012003181A2 (en) * | 2010-07-02 | 2012-01-05 | Fmc Corporation | Solid forms |
PL2603232T3 (en) | 2010-08-11 | 2020-05-18 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
US10869843B2 (en) | 2010-11-23 | 2020-12-22 | Chemi Nutra | Method for increasing muscle mass and strength |
US9532952B2 (en) * | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
WO2012103411A2 (en) | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Controlled-release melatonin composition and related methods |
EP2675297A4 (en) * | 2011-02-16 | 2014-10-01 | Wellbemed Sweden Ab | Foodstuff comprising an extract mixture |
WO2012143403A1 (en) * | 2011-04-18 | 2012-10-26 | Nestec S.A. | Nutritional compositions having alpha-hica and citrulline |
EP2776055B1 (en) | 2011-08-17 | 2016-12-14 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
WO2015050809A1 (en) * | 2013-10-01 | 2015-04-09 | Novozymes A/S | Processes of producing fermentation products |
EP2926669B1 (en) * | 2014-04-02 | 2017-05-24 | AlzChem AG | Creatine protein matrix and method for manufacturing the same |
MX2016014405A (en) * | 2014-05-05 | 2017-01-20 | Boehringer Ingelheim Int | Fast dissolving granulate. |
PL2974733T3 (en) * | 2014-07-14 | 2017-09-29 | Dr. Willmar Schwabe Gmbh & Co. Kg | Combination of valerian root extract and lavender oil for use in the treatment of sleep disorders |
AU2016297986B8 (en) | 2015-07-29 | 2020-06-11 | Advanced Bionutrition Corp. | Stable dry probiotic compositions for special dietary uses |
EP3368498A4 (en) | 2015-10-27 | 2019-06-12 | Cytozyme Animal Nutrition, Inc. | Animal nutrition compositions and related methods |
US10674746B2 (en) | 2015-10-27 | 2020-06-09 | Cytozyme Animal Nutrition, Inc. | Animal nutrition compositions and related methods |
CN106674057A (en) * | 2015-11-09 | 2017-05-17 | 江西乐维生物药业有限公司 | L-arginine alpha-ketoisocaproate preparation method |
WO2017109300A1 (en) * | 2015-12-22 | 2017-06-29 | Urgo Recherche Innovation Et Developpement | Combination product that helps relax and fall asleep |
CA3023305A1 (en) * | 2016-05-06 | 2017-11-09 | Physician's Seal, LLC | Valerian composition and related methods |
JP7007798B2 (en) * | 2016-09-13 | 2022-02-10 | オリザ油化株式会社 | Circadian rhythm improver |
JP6909569B2 (en) * | 2016-09-16 | 2021-07-28 | オリザ油化株式会社 | Skin quality improver |
ES2684414B1 (en) * | 2017-03-31 | 2019-12-11 | Laboratorios Vinas S A | Galenic composition, for oral use, comprising micronized melatonin and a zinc salt and corresponding method and use |
EP3641759B1 (en) | 2017-06-20 | 2024-04-03 | Société des Produits Nestlé S.A. | Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva |
JP2020525549A (en) * | 2017-06-27 | 2020-08-27 | ハーモニクス エルエルシー | Sustained-release sleep aid system |
JP6837700B2 (en) | 2017-09-08 | 2021-03-03 | インシグニス セラピュティクス, インコーポレイテッドInsignis Therapeutics, Inc. | How to use dipivefrine |
US10639340B2 (en) * | 2018-06-18 | 2020-05-05 | Eric Young | Method of drying botanicals |
KR102154074B1 (en) | 2018-10-17 | 2020-09-09 | 한국 한의학 연구원 | Composition for preventing, ameliorating or treating sleep disturbance comprising flavonoid compound as effective component |
CN110876691A (en) * | 2019-10-29 | 2020-03-13 | 广东润和生物科技有限公司 | Coenzyme Q10Sleep-aiding skin-beautifying massage emulsion |
CN113133307A (en) | 2019-10-31 | 2021-07-16 | 马克一创新中心有限公司 | Composition comprising mulberry extract and method for producing the same |
US20210299166A1 (en) * | 2020-03-25 | 2021-09-30 | Allgood Beverage Company | Compositions for maintaining electrolyte balance and urinary tract health |
EP4255399A1 (en) * | 2020-12-01 | 2023-10-11 | Seattle Gummy Company | Ped5 inhibitor semi-solid compositions and methods of making and using thereof |
US20220347119A1 (en) * | 2021-04-30 | 2022-11-03 | Reshma N. Kheraj | Medicated drink |
US11833182B2 (en) | 2021-08-10 | 2023-12-05 | Shaklee Corporation | Sleep product |
CN114027508A (en) * | 2021-12-03 | 2022-02-11 | 龙岩学院 | Functional food gamma-aminobutyric acid compound preparation for improving sleep |
WO2023107990A1 (en) * | 2021-12-08 | 2023-06-15 | Nutramax Laboratories, Inc. | Supplemental coating and related method |
DE102022114966A1 (en) | 2022-06-14 | 2023-12-14 | Alzchem Trostberg Gmbh | Water-soluble creatine agglomerate |
CN115381890A (en) * | 2022-08-01 | 2022-11-25 | 澳美制药(苏州)有限公司 | Sleep-aiding sustained-release tablet and preparation method thereof |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4006025A (en) * | 1975-06-06 | 1977-02-01 | Polaroid Corporation | Process for dispersing sensitizing dyes |
US4294917A (en) * | 1979-05-22 | 1981-10-13 | Ciba-Geigy Ag | Photographic silver halide material containing a dye filter or a dye anti-halation layer |
US4294916A (en) * | 1979-05-22 | 1981-10-13 | Ciba-Geigy Ag | Photographic silver halide material containing a dye filter or a dye anti-halation layer |
US4490654A (en) * | 1983-06-10 | 1984-12-25 | The Arthur G. Russell Company, Incorporated | Control circuit for vibratory devices |
US4927744A (en) * | 1988-08-05 | 1990-05-22 | Eastman Kodak Company | Photographic element having solid particle dispersion oxidized developer scavenger |
US4950586A (en) * | 1988-12-23 | 1990-08-21 | Eastman Kodak Company | Solid particle dispersions of filter dyes for photographic elements |
US5547683A (en) * | 1992-10-09 | 1996-08-20 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Method for producing microgranulated particle |
US5726146A (en) * | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
US6604698B2 (en) * | 2000-05-10 | 2003-08-12 | Skyepharma Canada, Inc. | Media milling |
US6634576B2 (en) * | 2000-08-31 | 2003-10-21 | Rtp Pharma Inc. | Milled particles |
US20040169096A1 (en) * | 1997-07-18 | 2004-09-02 | Hahn William E. | Process for micronizing materials |
US6905707B2 (en) * | 1998-05-28 | 2005-06-14 | Medical Research Institute | Controlled release arginine alpha ketoglutarate |
US20050163857A1 (en) * | 2002-04-03 | 2005-07-28 | Ashok Rampal | Clarithromycin formulations having improved bioavailability |
US7118763B2 (en) * | 1993-11-19 | 2006-10-10 | Alkermes Controlled Therapeutics, Inc. Ii | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US20060251727A1 (en) * | 2005-04-11 | 2006-11-09 | Gardiner Paul T | Supplemental dietary composition for increasing muscle size, strength, athletic performance and/or exercise capacity |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2057420B (en) * | 1979-08-30 | 1984-05-10 | Standard Telephones Cables Ltd | Controlled release glass |
US4781925A (en) * | 1986-03-06 | 1988-11-01 | American Home Products Corporation | Calcium supplement compressed tablets |
US5520932A (en) * | 1988-06-24 | 1996-05-28 | The Upjohn Company | Fine-milled colestipol hydrochloride |
US5242941A (en) * | 1990-12-04 | 1993-09-07 | State Of Oregon | Methods of treating circadian rhythm disorders |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
HUT62477A (en) * | 1991-10-07 | 1993-05-28 | Sandor Milesz | Herb mixture |
GB9215746D0 (en) * | 1992-07-24 | 1992-09-09 | Hultman Eric | A method of increasing creatine supply depot |
US5449683A (en) | 1992-10-01 | 1995-09-12 | Massachussetts Institute Of Technology | Methods of inducing sleep using melatonin |
IT1271687B (en) * | 1994-08-04 | 1997-06-04 | Flamma Spa | WATER SOLUBLE ORGANIC SALTS OF CREATINE |
JPH07252148A (en) * | 1994-10-08 | 1995-10-03 | Masahiro Nagahama | Therapeutic agent for diabetes |
GB9517443D0 (en) * | 1994-12-17 | 1995-10-25 | Univ Nottingham | Increasing creatine and glycogen concentration in muscle |
US5541801A (en) * | 1995-05-26 | 1996-07-30 | United Microelectronics Corporation | Low-voltage gate trigger SCR (LVGTSCR) ESD protection circuit for input and output pads |
US5681578A (en) * | 1996-01-22 | 1997-10-28 | Sahley; Billie J. | Composition for relieving stress anxiety, grief, and depression |
NZ330739A (en) * | 1996-05-20 | 1999-06-29 | Janssen Pharmaceutica Nv | Particulate solid dispersion of itraconazole and a water soluble polymer |
US8128955B2 (en) * | 1996-05-31 | 2012-03-06 | The Original Creatine Patent Company | Food compositions containing creatine |
GB9611356D0 (en) * | 1996-05-31 | 1996-08-07 | Howard Alan N | Improvements in or relating to compositions containing Creatine, and other ergogenic compounds |
US6361794B1 (en) * | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
US6080410A (en) * | 1997-03-17 | 2000-06-27 | Natrol, Inc. | Method for reducing daily stress and anxiety in adults |
US6100287A (en) * | 1997-11-13 | 2000-08-08 | University Of Florida | Materials and methods for enhancing muscle performance and recovery from fatigue |
US5955107A (en) * | 1997-12-12 | 1999-09-21 | Fmc Corporation | Pharmaceutical suspension tablet compositions |
CA2246014C (en) * | 1998-08-21 | 2001-12-11 | Paul T. Gardiner | Food supplements and methods comprising lipoic acid and creatine |
US6136339A (en) * | 1998-08-21 | 2000-10-24 | Gardiner; Paul T. | Food supplements and methods comprising lipoic acid and creatine |
US6599530B2 (en) * | 1998-09-14 | 2003-07-29 | Orion Corporation | Oral compacted composition comprising catechol derivatives |
FR2789997B1 (en) * | 1999-02-18 | 2004-12-03 | Rhodia Chimie Sa | COMPOSITION COMPRISING AN OIL IN WATER EMULSION AND AN INORGANIC AGENT |
US6383527B1 (en) * | 1999-03-04 | 2002-05-07 | Nps Pharmaceuticals, Inc. | Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID |
US6245352B1 (en) * | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
US9486429B2 (en) * | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US6869622B2 (en) * | 1999-07-21 | 2005-03-22 | Ancile Pharmaceuticals, Inc. | Composition for improving sleep quality and efficiency, and methods of preparing and using the composition |
US6653352B2 (en) * | 1999-09-29 | 2003-11-25 | Medical Merchandising, Inc. | Pain reliever and method of use |
US6312736B1 (en) * | 1999-12-09 | 2001-11-06 | Biotech Corporation | Herbal composition to relieve pain |
US20010041675A1 (en) * | 2000-01-24 | 2001-11-15 | Jacobs Robert H. | Satisfy composition and method of weight control |
US20020076437A1 (en) * | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
US6399116B1 (en) * | 2000-04-28 | 2002-06-04 | Rulin Xiu | Rhodiola and used thereof |
US6277396B1 (en) * | 2000-05-11 | 2001-08-21 | Maximum Human Performance, Inc. | Dietary supplement containing a thermogenic substance and an adrenal support substance |
AUPR177300A0 (en) * | 2000-11-29 | 2000-12-21 | Centre For Molecular Biology And Medicine | Therapeutic methods |
US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
US20050129783A1 (en) * | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
JP2002371003A (en) * | 2001-06-15 | 2002-12-26 | Kikkoman Corp | Inhibitor against blood sugar level increase |
US20030013639A1 (en) * | 2001-07-03 | 2003-01-16 | Lisa Yurchak | Sleep inducing antacid composition |
CN1625406A (en) * | 2001-08-09 | 2005-06-08 | 底古萨食品配料有限公司 | Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
EP1446135B1 (en) * | 2001-09-17 | 2007-07-25 | Phytos Inc. | Standardized extracts of scutellaria lateriflora |
US6770263B1 (en) * | 2001-10-01 | 2004-08-03 | Naturewell, Incorporated | Compositions and methods for the treatment of aches and pains |
US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
DE10208335A1 (en) * | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Pharmaceutical form and process for its preparation |
US6903136B2 (en) * | 2002-04-22 | 2005-06-07 | Experimental And Applied Sciences, Inc. | Food supplements containing 4-hydroxyisoleucine and creatine |
US20030232091A1 (en) * | 2002-06-17 | 2003-12-18 | Adi Shefer | Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof |
US20040005368A1 (en) * | 2002-07-01 | 2004-01-08 | Morris Mann | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite |
US7625362B2 (en) * | 2003-09-16 | 2009-12-01 | Boehringer Technologies, L.P. | Apparatus and method for suction-assisted wound healing |
US6703412B1 (en) * | 2002-09-27 | 2004-03-09 | Holly A. Rosenthal | Method of treating sleeplessness with melatonin on an acute basis |
AU2003283004A1 (en) * | 2002-10-22 | 2004-05-13 | Waratah Pharmaceuticals, Inc. | Treatment of diabetes |
EP1562555A2 (en) * | 2002-10-24 | 2005-08-17 | Enos Pharmaceuticals, Inc. | Sustained release l-arginine formulations and methods of manufacture and use |
US6946151B2 (en) * | 2002-11-12 | 2005-09-20 | Ayurvedic-Life International, Llc | Therapeutic compositions |
US20040247699A1 (en) * | 2002-12-20 | 2004-12-09 | Bernardina Johanna Martina Delsing | Method for the prevention or treatment of overweight in mammals |
JP2004217532A (en) * | 2003-01-10 | 2004-08-05 | Maruzen Pharmaceut Co Ltd | Mulberry leaf extract and method for producing the same, and anti-hyperglycemic composition and obesity-preventing composition |
WO2004073632A2 (en) * | 2003-02-19 | 2004-09-02 | Biovail Laboratories Inc. | Rapid absorption selective 5-ht agonist formulations |
US8512727B2 (en) * | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
US7129273B2 (en) * | 2003-04-30 | 2006-10-31 | Creative Compounds, Llc | Dicreatine Malate |
CN1257259C (en) * | 2003-06-21 | 2006-05-24 | 陈豪锋 | Formulation for health-care red rice wine |
EP1686976A2 (en) * | 2003-11-05 | 2006-08-09 | Santarus, Inc. | Combination of proton pump inhibitor and sleep aid |
ES2366646T3 (en) * | 2003-11-05 | 2011-10-24 | Elan Pharma International Limited | COMPOSITIONS IN THE FORM OF NANOPARTICLES THAT HAVE A PEPTIDE AS A SURFACE STABILIZER. |
DE10352822A1 (en) * | 2003-11-12 | 2005-06-23 | Bioghurt Biogarde Gmbh & Co. Kg | Use of an additionally fermented cereal sludge for the prevention and / or treatment of elevated blood sugar levels |
US8337915B2 (en) * | 2004-01-10 | 2012-12-25 | S George Aburdeineh | Fenugreek seed extract to lower blood cholesterol |
MXPA06009377A (en) * | 2004-02-20 | 2007-03-07 | Lifescape Biosciences Inc | Compositions and methods for sleep regulation. |
DE102004008804A1 (en) * | 2004-02-20 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Multilayer tablet |
BRPI0506793A (en) * | 2004-02-20 | 2007-05-22 | Rinat Neuroscience Corp | Obesity or diabetes treatment methods using nt-4/5 |
DE102004009962A1 (en) * | 2004-03-01 | 2005-09-22 | Degussa Ag | Use of guanidine compounds as physiological restorative in the form of nutritional supplements, feed additives, in cosmetic preparations and as plant strengthening agents |
ATE477809T1 (en) * | 2004-04-06 | 2010-09-15 | Taiyokagaku Co Ltd | USE OF A COMBINATION OF THEANINE AND SEROTONIN FOR SLEEP DISORDER |
CN1568803A (en) * | 2004-04-30 | 2005-01-26 | 南阳市海达生物技术有限公司 | Food with blood-sugar/blood-fat reducing function and preparation method thereof |
US20050249843A1 (en) * | 2004-05-07 | 2005-11-10 | Loren Wallis | Low carbohydrate caramel corn composition |
US20050282870A1 (en) * | 2004-06-16 | 2005-12-22 | Carter Stephen G | Peripherally-acting vasodilators |
DE102004036047A1 (en) * | 2004-07-24 | 2006-02-23 | Bioghurt Biogarde Gmbh & Co. Kg | Physiologically active composition |
CA2577963C (en) * | 2004-08-25 | 2015-10-06 | Mtor Formulations Ltd. | Compositions and methods for activating protein synthesis and deactivating catabolic processes in skeletal muscle |
US20060083793A1 (en) * | 2004-09-29 | 2006-04-20 | Gardiner Paul T | Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker |
CA2516678A1 (en) * | 2005-08-18 | 2007-02-18 | Gakic Formulations Ltd. | Supplemental dietary composition for enhancing muscle performance and/or recovery from fatigue |
-
2006
- 2006-07-14 JP JP2008555578A patent/JP2009527504A/en active Pending
- 2006-07-14 CA CA002642761A patent/CA2642761A1/en not_active Abandoned
- 2006-07-14 AU AU2006338839A patent/AU2006338839A1/en not_active Abandoned
- 2006-07-14 WO PCT/CA2006/001156 patent/WO2007095716A1/en active Application Filing
- 2006-07-14 EP EP06761118A patent/EP1991241A4/en not_active Withdrawn
- 2006-07-14 US US11/486,866 patent/US7476405B2/en active Active
- 2006-08-16 US US11/505,779 patent/US7794749B2/en not_active Expired - Fee Related
- 2006-08-16 CA CA2556305A patent/CA2556305C/en not_active Expired - Fee Related
- 2006-08-16 EP EP06775120A patent/EP1996199A4/en not_active Withdrawn
- 2006-08-16 AU AU2006338840A patent/AU2006338840A1/en not_active Abandoned
- 2006-08-16 WO PCT/CA2006/001345 patent/WO2007095717A1/en active Application Filing
- 2006-09-14 US US11/522,266 patent/US7749547B2/en not_active Expired - Fee Related
- 2006-09-14 WO PCT/CA2006/001512 patent/WO2007095718A1/en active Application Filing
- 2006-09-14 CA CA2560107A patent/CA2560107C/en active Active
-
2007
- 2007-02-21 WO PCT/CA2007/000263 patent/WO2007095734A1/en active Application Filing
- 2007-02-21 US US11/709,525 patent/US20070202165A1/en not_active Abandoned
- 2007-02-21 US US11/709,526 patent/US20070202166A1/en not_active Abandoned
- 2007-02-21 WO PCT/CA2007/000262 patent/WO2007095733A1/en active Search and Examination
- 2007-06-21 US US11/821,229 patent/US7906154B2/en not_active Expired - Fee Related
-
2008
- 2008-09-01 ZA ZA200807489A patent/ZA200807489B/en unknown
- 2008-09-09 US US12/206,892 patent/US7914826B2/en not_active Expired - Fee Related
- 2008-11-10 US US12/291,482 patent/US20090142410A1/en not_active Abandoned
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4006025A (en) * | 1975-06-06 | 1977-02-01 | Polaroid Corporation | Process for dispersing sensitizing dyes |
US4294917A (en) * | 1979-05-22 | 1981-10-13 | Ciba-Geigy Ag | Photographic silver halide material containing a dye filter or a dye anti-halation layer |
US4294916A (en) * | 1979-05-22 | 1981-10-13 | Ciba-Geigy Ag | Photographic silver halide material containing a dye filter or a dye anti-halation layer |
US4490654A (en) * | 1983-06-10 | 1984-12-25 | The Arthur G. Russell Company, Incorporated | Control circuit for vibratory devices |
US4927744A (en) * | 1988-08-05 | 1990-05-22 | Eastman Kodak Company | Photographic element having solid particle dispersion oxidized developer scavenger |
US4950586A (en) * | 1988-12-23 | 1990-08-21 | Eastman Kodak Company | Solid particle dispersions of filter dyes for photographic elements |
US5547683A (en) * | 1992-10-09 | 1996-08-20 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Method for producing microgranulated particle |
US7118763B2 (en) * | 1993-11-19 | 2006-10-10 | Alkermes Controlled Therapeutics, Inc. Ii | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US5726146A (en) * | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
US20040169096A1 (en) * | 1997-07-18 | 2004-09-02 | Hahn William E. | Process for micronizing materials |
US6905707B2 (en) * | 1998-05-28 | 2005-06-14 | Medical Research Institute | Controlled release arginine alpha ketoglutarate |
US6604698B2 (en) * | 2000-05-10 | 2003-08-12 | Skyepharma Canada, Inc. | Media milling |
US6634576B2 (en) * | 2000-08-31 | 2003-10-21 | Rtp Pharma Inc. | Milled particles |
US20050163857A1 (en) * | 2002-04-03 | 2005-07-28 | Ashok Rampal | Clarithromycin formulations having improved bioavailability |
US20060251727A1 (en) * | 2005-04-11 | 2006-11-09 | Gardiner Paul T | Supplemental dietary composition for increasing muscle size, strength, athletic performance and/or exercise capacity |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009094750A1 (en) * | 2008-01-31 | 2009-08-06 | Northern Innovations And Formulations Corp. | Fast dissolution amino acid composition |
US20090203789A1 (en) * | 2008-01-31 | 2009-08-13 | Multi Formulations Ltd. | Fast Dissolution Amino Acid Composition |
US9981906B2 (en) | 2011-08-04 | 2018-05-29 | Repros Therapeutics Inc. | Trans-clomiphene metabolites and uses thereof |
US9675564B2 (en) | 2011-12-02 | 2017-06-13 | Asoltech S.R.L. | Composition based on ubidecarenone |
CN104582686A (en) * | 2012-08-21 | 2015-04-29 | 利普生物药剂公司 | Trans-clomiphene formulations and uses thereof |
US20150202167A1 (en) * | 2012-08-21 | 2015-07-23 | Repros Therapeutics Inc. | Trans-Clomiphene Formulations and Uses Thereof |
JP2015527360A (en) * | 2012-08-21 | 2015-09-17 | レプロス セラピューティクス インコーポレイティド | Trans-clomiphene formulations and uses thereof |
US9687458B2 (en) | 2012-11-02 | 2017-06-27 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
US9968567B2 (en) | 2014-11-14 | 2018-05-15 | Asoltech S.R.L. | Composition based on COQ10 |
Also Published As
Publication number | Publication date |
---|---|
CA2556305A1 (en) | 2007-08-23 |
CA2642761A1 (en) | 2007-08-30 |
US7914826B2 (en) | 2011-03-29 |
CA2556305C (en) | 2013-08-06 |
ZA200807489B (en) | 2009-11-25 |
WO2007095716A1 (en) | 2007-08-30 |
CA2560107C (en) | 2016-03-29 |
WO2007095733A1 (en) | 2007-08-30 |
EP1996199A1 (en) | 2008-12-03 |
EP1991241A1 (en) | 2008-11-19 |
US20070196470A1 (en) | 2007-08-23 |
AU2006338839A1 (en) | 2007-08-30 |
WO2007095734A1 (en) | 2007-08-30 |
WO2007095718A1 (en) | 2007-08-30 |
US7749547B2 (en) | 2010-07-06 |
CA2560107A1 (en) | 2007-08-23 |
JP2009527504A (en) | 2009-07-30 |
US7794749B2 (en) | 2010-09-14 |
US7476405B2 (en) | 2009-01-13 |
EP1996199A4 (en) | 2009-07-15 |
US20070196348A1 (en) | 2007-08-23 |
US20070202165A1 (en) | 2007-08-30 |
US20070196508A1 (en) | 2007-08-23 |
EP1991241A4 (en) | 2009-07-08 |
US20090142410A1 (en) | 2009-06-04 |
US20070264337A1 (en) | 2007-11-15 |
AU2006338840A1 (en) | 2007-08-30 |
US7906154B2 (en) | 2011-03-15 |
US20090011015A1 (en) | 2009-01-08 |
WO2007095717A1 (en) | 2007-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070202166A1 (en) | Method for increasing the rate and consistency of bioavailability of supplemental dietary ingredients | |
JP7320485B2 (en) | Abiraterone acetate preparation | |
JP5439366B2 (en) | Cellulose powder excellent in segregation preventing effect and composition thereof | |
JP5240822B2 (en) | Porous cellulose aggregate and molded body composition thereof | |
JP6141013B2 (en) | Production of encapsulated nanoparticles on a commercial scale | |
KR101824831B1 (en) | A Novel formulation of meloxicam | |
Zhou et al. | Preparation of tripterine nanostructured lipid carriers and their absorption in rat intestine | |
US20070190017A1 (en) | Porous cellulose aggregate and formed product composition comprising the same | |
KR102491439B1 (en) | Abiraterone acetate formulation and methods of use | |
US20120225118A1 (en) | Compositions for delivery of insoluble agents | |
KR19990072754A (en) | Method for producing water dispersible sterol formulations | |
WO2013171697A1 (en) | Oral composition comprising a low- availability active ingredient, for use as a medicament or a dietary/supplement/nutraceutical | |
WO2006122965A1 (en) | Compositions for enteral application of microorganisms | |
WO2007038596A2 (en) | Phytosterol nutritional supplements | |
Ding et al. | Characterisation of spray dried microencapsules with amorphous lutein nanoparticles: Enhancement of processability, dissolution rate, and storage stability | |
TWI729476B (en) | Cellulose powder, its use and lozenges | |
CN113260359A (en) | Alcohol antidote | |
US20130251815A1 (en) | Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles | |
US20090203789A1 (en) | Fast Dissolution Amino Acid Composition | |
CN108354905A (en) | A kind of andrographolide solid dispersion of stabilization and preparation method thereof and preparation | |
KR100750727B1 (en) | Composition and formulation containing chitosan | |
Lu et al. | Development and evaluation of aceclofenac loaded lipospheres for the treatment of osteoarthritis | |
JP2005255618A (en) | Solid pharmaceutical preparation composition comprising slightly water-soluble active ingredient and porous cellulose particle | |
JPH03151326A (en) | Method for improvement of biological usefulness of pharmaceutically effective substance having peptide bond | |
Aung et al. | Impact of Polymers as Precipitation Inhibitors on Physicochemical Properties of Spray-Dried Astaxanthin-Loaded Self-Microemulsifying Delivery Systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IML FORMULATIONS LTD., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HEUER, MARVIN A.;CLEMENT, KEN;CHAUDHURI, SHAN;REEL/FRAME:019232/0991;SIGNING DATES FROM 20070417 TO 20070424 |
|
AS | Assignment |
Owner name: MULTI FORMULATIONS LTD., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IML FORMULATIONS LTD.;REEL/FRAME:020013/0280 Effective date: 20071017 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |